CR
SRPT icon

Cooperatieve Rabobank’s Sarepta Therapeutics SRPT Stock Holding History

Cooperatieve Rabobank’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-5,952
Closed -$226K – 152
2013
Q2 		$226K Buy
+5,952
New +$213K 0.08% 139

Other funds holding SRPT

Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Cooperatieve Rabobank's SRPT Position: Q3 2013 in Review

Cooperatieve Rabobank sold out of Sarepta Therapeutics (SRPT) in Q3 2013, closing a stake of 5,952 shares — an estimated $226K sold.

Cooperatieve Rabobank first reported a position in SRPT in Q2 2013 and held it in 1 quarter. The position peaked at $226K in Q2 2013. 134 funds tracked by Wall St. Rank hold SRPT as of Q3 2013.

  • Cooperatieve Rabobank reported no remaining Sarepta Therapeutics position as of Q3 2013 after selling out during the quarter.
  • Cooperatieve Rabobank sold 5,952 Sarepta Therapeutics shares in Q3 2013, an estimated $226K.
  • Cooperatieve Rabobank first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 1 quarter.
  • Cooperatieve Rabobank's Sarepta Therapeutics position peaked at $226K in Q2 2013.
  • 134 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2013.

Based on Cooperatieve Rabobank's 13F filing for Q3 2013, filed 14 Nov 2013.